Forum Topic News
  • Conversation: Eli Lilly discontinues Ph II trials for arthritis drug

    • February 20, 2018 10:07 AM GMT
      • Post(s)
        549

      Eli Lilly discontinues Ph II trials for arthritis drug

      In March 2015, Hanmi signed an exclusive license agreement with the US-based drug maker to grant rights to HM71224 in a deal that could generate up to $640 million
      Korea’s Hanmi Pharma recently announced that its partner Eli Lilly has discontinued the clinical study for HM71224, an experimental Bruton’s tyrosine kinase inhibitor for the treatment of rheumatoid arthritis because it is “unlikely to meet the primary efficacy endpoint in the ongoing phase 2 trials.”
      Shares of Hanmi Pharmaceutical dropped sharply on Feb. 19 after Eli Lilly decided to stop clinical trials, according to the country’s local press reports.
      In March 2015, Hanmi signed an exclusive license agreement with the US-based drug maker to grant rights to HM71224 in a deal that could generate up to $640 million.
      Read more: http://bit.ly/2CyoKGO

Add Reputation

Do you want to add reputation for this member by this post?

or cancel